Dr. Melissa Alsina, MD

Dr. Alsina practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Alsina's NPI, 1184656746, was assigned on July 6, 2006. Dr. Alsina graduated from University of Puerto Rico, Medical Sciences Campus in 1988. Dr. Alsina holds Florida license ME84554.

Dr. Alsina's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Alsina's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Alsina to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alsina practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Alsina's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Alsina is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Alsina's licenses on file in 4 states: Florida, Puerto Rico, Oklahoma and Texas.

Dmand AI lists multiple myeloma among the conditions Dr. Alsina treats.

CMS data shows 386 Medicare services from Dr. Alsina across 5 procedure codes in 2024, for 181 Medicare patients. Medicare paid $30,030 for them.

CMS counts 181 Medicare patients who saw Dr. Alsina in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alsina's median patient age at 69, with 47% women.

In 2024, Dr. Alsina wrote 768 Medicare Part D claims for 136 patients. 70% of them were for generic drugs. CMS names the drug for 606 of them, across 13 drugs with 11 or more claims each, at $5,526,033 in total drug cost. In 2023, CMS named 513 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Alsina for performance year 2024, reported as part of a group. Dr. Alsina accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alsina as offering telehealth.

Dmand AI links 115 papers to Dr. Alsina, published from 2003 to 2025. 2015 was the busiest year, with 7. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Hematopoietic Stem Cell Transplantation. Dr. Alsina has published most often in Blood. Dr. Alsina's most frequent co-authors are Taiga Nishihori, MD, Frederick Lundry Locke, MD and Kenneth H. Shain, MD.

Dmand AI links Dr. Alsina to 17 clinical trials, 8 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Bronchiolitis Obliterans Syndrome. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 14.

CMS Open Payments shows 133 general payments to Dr. Alsina from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Celgene Corporation paid the most, $22,645. It also lists 1 research payment totaling $2,156 in 2016.

Dr. Alsina graduated from University of Puerto Rico, Medical Sciences Campus in 1988.

Dr. Alsina is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.